Laboratorios Farmaceuticos Rovi, S.A.

BME:ROVI Stok Raporu

Piyasa değeri: €4.0b

Laboratorios Farmaceuticos Rovi Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Laboratorios Farmaceuticos Rovi yıllık ortalama 30% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 13.1% annual. Gelirler growing yılda ortalama 19.2% oranında artmaktadır. Laboratorios Farmaceuticos Rovi'in özkaynak karlılığı 30.7% ve net marjı 19%'dir.

Anahtar bilgiler

30.0%

Kazanç büyüme oranı

30.2%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi5.0%
Gelir büyüme oranı19.2%
Özkaynak getirisi30.7%
Net Marj19.0%
Sonraki Kazanç Güncellemesi07 Nov 2024

Yakın geçmiş performans güncellemeleri

Recent updates

With Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) It Looks Like You'll Get What You Pay For

Oct 21
With Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) It Looks Like You'll Get What You Pay For

Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?

Aug 29
Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?

Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?

Jul 15
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?

We Take A Look At Why Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) CEO Has Earned Their Pay Packet

Jun 17
We Take A Look At Why Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) CEO Has Earned Their Pay Packet

Why We're Not Concerned About Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) Share Price

May 08
Why We're Not Concerned About Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) Share Price

These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well

Apr 17
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well

Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 26% Discount?

Feb 14
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 26% Discount?

Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly

Dec 21
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly

Is There An Opportunity With Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) 34% Undervaluation?

Nov 03
Is There An Opportunity With Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) 34% Undervaluation?

Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly

Aug 26
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly

Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 27% Below Their Intrinsic Value Estimate

Jul 14
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 27% Below Their Intrinsic Value Estimate

Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?

May 26
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?

Do Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings Warrant Your Attention?

May 05
Do Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings Warrant Your Attention?

Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 22% Below Their Intrinsic Value Estimate

Apr 11
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 22% Below Their Intrinsic Value Estimate

Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?

Feb 22
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?

An Intrinsic Calculation For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Suggests It's 48% Undervalued

Dec 10
An Intrinsic Calculation For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Suggests It's 48% Undervalued

These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely

Nov 04
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely

Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?

Sep 15
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?

Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?

Aug 28
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?

Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly

Jun 15
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly

I Ran A Stock Scan For Earnings Growth And Laboratorios Farmaceuticos Rovi (BME:ROVI) Passed With Ease

Feb 13
I Ran A Stock Scan For Earnings Growth And Laboratorios Farmaceuticos Rovi (BME:ROVI) Passed With Ease

Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?

Jan 02
Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?

A Look At The Fair Value Of Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)

Dec 12
A Look At The Fair Value Of Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)

Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching

Nov 02
Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching

We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt

Sep 24
We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt

Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching

Jun 02
Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching

We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt

Apr 06
We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt

Investors Who Bought Laboratorios Farmaceuticos Rovi (BME:ROVI) Shares Five Years Ago Are Now Up 205%

Mar 15
Investors Who Bought Laboratorios Farmaceuticos Rovi (BME:ROVI) Shares Five Years Ago Are Now Up 205%

If You Like EPS Growth Then Check Out Laboratorios Farmaceuticos Rovi (BME:ROVI) Before It's Too Late

Feb 16
If You Like EPS Growth Then Check Out Laboratorios Farmaceuticos Rovi (BME:ROVI) Before It's Too Late

Are Strong Financial Prospects The Force That Is Driving The Momentum In Laboratorios Farmaceuticos Rovi, S.A.'s BME:ROVI) Stock?

Jan 26
Are Strong Financial Prospects The Force That Is Driving The Momentum In Laboratorios Farmaceuticos Rovi, S.A.'s BME:ROVI) Stock?

These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well

Jan 04
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well

Announcing: Laboratorios Farmaceuticos Rovi (BME:ROVI) Stock Increased An Energizing 169% In The Last Five Years

Dec 14
Announcing: Laboratorios Farmaceuticos Rovi (BME:ROVI) Stock Increased An Energizing 169% In The Last Five Years

Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Growing Earnings But Are They A Good Guide?

Nov 26
Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Growing Earnings But Are They A Good Guide?

Gelir ve Gider Dağılımı

Laboratorios Farmaceuticos Rovi nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

BME:ROVI Gelir, gider ve kazançlar (EUR Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 247781481530
31 Mar 247791381500
31 Dec 238301701470
30 Sep 238371971430
30 Jun 238181861380
31 Mar 238141941340
31 Dec 228182001300
30 Sep 227611761150
30 Jun 227391831100
31 Mar 227241821080
31 Dec 216491531030
30 Sep 21581113950
30 Jun 2151982940
31 Mar 2145071860
31 Dec 2042061850
30 Sep 2041355930
30 Jun 2039553910
31 Mar 2040046930
31 Dec 1938139920
30 Sep 1935533930
30 Jun 1933427930
31 Mar 1931018910
31 Dec 1830318910
30 Sep 1829116900
30 Jun 182839880
31 Mar 1828418870
31 Dec 1727617850
30 Sep 1727722810
30 Jun 1727524810
31 Mar 1727223800
31 Dec 1626526800
30 Sep 1626025840
30 Jun 1625424840
31 Mar 1624623850
31 Dec 1524620840
30 Sep 152422153-9
30 Jun 1524323780
31 Mar 1524125760
31 Dec 1423824750
30 Sep 1423024771
30 Jun 1422424770
31 Mar 1422124780
31 Dec 1321823760

Kaliteli Kazançlar: ROVI yüksek düzeyde nakit dışı kazança sahiptir.

Büyüyen Kar Marjı: ROVI 'nin mevcut net kar marjları (19%) geçen yılın (22.7%) değerinden daha düşüktür.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: ROVI şirketinin kazançları son 5 yılda yılda 30% oranında önemli ölçüde arttı.

Büyüme Hızlandırma: ROVI 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: ROVI geçtiğimiz yıl negatif kazanç büyümesine ( -20.3% ) sahipti ve bu da onu Pharmaceuticals sektör ortalamasıyla ( 4.5% ) karşılaştırmayı zorlaştırıyordu.


Özkaynak Getirisi

Yüksek ROE: ROVI 'nin Özsermaye Getirisi ( 30.7% ) yüksek olarak değerlendiriliyor.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin